Miami Breast Cancer Conference (MBCC)

Independent variables, such as the burden of disease prior to treatment, molecular prognosis, sensitivity to chemotherapy, sensitivity to endocrine therapy, and sensitivity to other treatments could be effective in predicting risk of recurrence in patients with breast cancer.

Kevin Kalinsky, MD, MS, discussed a number of antibody-drug conjugates, detailing the prevailing data and potential trials that may change the treatment paradigm for patients with breast cancer.

Mandar Aras, MD, PhD, discussed the management and prevention of cardiotoxicity in patients receiving systemic therapy for breast cancer at the 38th Annual Miami Breast Cancer Conference, hosted by Physicians’ Education Resource®, LLC.

Allowing for the use of antiemetic prophylaxis and anti-diarrheal medication in the phase 3 KX-ORAX-001 study reduced study drug-related gastrointestinal adverse events.

At the Miami Breast Cancer Conference, Debu Tripathy, MD, reviewed adaptive therapy for the adjuvant treatment of patients with HER2-positive, early-stage breast cancer.

Data focusing on patients seeking breast surgical procedures determined that broad skill sets are valuable for general surgeons practicing in rural areas, as breast surgeries only represented a small proportion of total surgical procedures conducted.

The addition of neratinib to capecitabine improved progression-free survival and central nervous system outcomes in patients with HER2-positive metastatic breast cancer with central nervous system disease.

More patients with early-stage estrogen receptor–positive breast cancer with high recurrence scores received chemotherapy following radiation in a single-institution study, and this resulted in a low recurrence rate across all patients examined.

The analysis of the KEYNOTE-119 study presented at the Miami Breast Cancer Conference, hosted by Physicians’ Education Resource®, LLC®, found trends estimating a significant role for tumor cell expression in PD-L1 as a predictive biomarker for pembrolizumab efficacy.

The clinical nurse specialist was also diagnosed with stage III invasive lobular breast cancer and was treated with CDK 4/6 inhibitors, giving her the unique opportunity to speak to both the patient and clinical perspective.

The geriatric oncologist spoke about the differences in treating older women and younger women with triple-negative breast cancer.

The breast medical oncologist discussed new treatment options for triple negative breast cancer as new targets become readily available for this aggressive cancer type.

The breast oncologist from the University of California, San Francisco, discussed new agents being developed in the breast cancer space.

The breast cancer expert spoke about decreasing the amount of treatment to receive the same impact for patients with breast cancer.

After a serious adverse reaction to a clinical trial put her in critical condition, Barbara Bigelow now shows no signs of breast cancer and is no longer on any cancer medications.

At the 37th Annual Miami Breast Cancer Conference, Valerie Lemaine, MD, MPH, FRCSC, told physicians what they need should know and discuss with their patients about BIA-ALCL.

Scott Gottlieb, MD, spoke about the spread of the novel coronavirus (COVID-19) during the keynote address at the 37th Annual Miami Breast Cancer Conference®.

The goal of the study is to determine the effect of adagloxad simolenin administered with the potent adjuvant OBI-821 as a therapeutic vaccine treatment on improving invasive disease-free survival in the study population.

Aditya Bardia, MD, MPH detailed the clinical development of antibody drug conjugates in patients with metastatic triple negative breast cancer, as well as what to expect moving forward with antibody drug conjugates in the metastatic breast cancer space.

As more agents become approved, it’s important to individualize therapy for this patient population, Sara A. Hurvitz, MD, said at the 37th Annual Miami Breast Cancer Conference.

The study found that 31 to 60 days seems to be the ideal time period to begin adjuvant chemotherapy in HER2-positive breast cancer patients.

This study sought to determine the patient and tumor characteristics associated with positive lymph nodes status in T1 HER2-positive breast cancer.

During the 2018 Miami Breast Cancer Conference, cardiologist Dr. Jean-Bernard Durand discussed protecting patients who are being treated with anthracyclines and HER2-targeted therapies from serious cardiac adverse events.

At the 2018 Miami Breast Cancer Conference, Dr. Patrick Borgen presented information related to gene expression profiling as a tool for managing DCIS.

During the 2018 Miami Breast Cancer Conference, Dr. Sara Hurvitz discussed current management options for patients with early-stage HER2-positive breast cancer.

During the 2018 Miami Breast Cancer Conference, Dr. Elizabeth A. Mittendorf discussed immunotherapy concepts and strategies related to breast cancer.

Surgical oncologists can help reduce the risk of patients developing opioid dependence.

Breast conservation therapy is usually best for local treatment for stage II breast cancer-and biology, as well as stage, drives patient outcomes.

Despite breast tumors’ lower mutational loads than lung cancers and melanoma-cancers in which immunotherapy have shown particular promise-breast cancers are nevertheless immunogenic.

The United States Medicare Access and CHIP Reauthorization Act of 2015 quality- and payment-related provisions took effect January 1, 2017, and how oncologists comply this year will determine their payments in 2019.